# 64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer

Source: https://onco.cc/trials/nct06970847/  
OnCo record `nct06970847` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of 64Cu-SAR-bisPSMA in prostate cancer, run by Clarity Pharmaceuticals Ltd, active and no longer recruiting.

## Summary

64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer is a phase 3 interventional study registered as NCT06970847 by Clarity Pharmaceuticals Ltd, with 220 participants enrolled, started 2025-05-16 and due to reach its primary completion in 2026-12-31. Interventions recorded: 64Cu-SAR-bisPSMA.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06970847
- Phase: 3
- Setting: 64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer
- Sponsor: Clarity Pharmaceuticals Ltd
- Enrolled: 220

## Sources

- ClinicalTrials.gov NCT06970847: https://clinicaltrials.gov/study/NCT06970847

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- companies: [Clarity Pharmaceuticals](https://onco.cc/companies/clarity-pharmaceuticals/)

---
JSON: https://onco.cc/api/v1/entities/nct06970847.json